Omeros Corporation OMER

$14.01 -3.71% at last close
Market Cap$1.08 billion
P/E Ratio—
Div Yield—
Volume1.29M
52-Week Range $6.24$21.24

Analyst Ratings

Consensus
Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
Avg. Price Target
$30.33 (+116.5% upside)

Full OMER forecast & analyst actions →

Key Stats

Today's Range
$13.80 – $14.71
50-Day Range
$12.70 – $21.24
52-Week Range
$6.24 – $21.24
Volume
1.29 million shs
Average Volume
1.30 million shs
Market Cap
$1.08 billion
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
9.61%
Days to Cover
19.62

About Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
175
Exchange
XNAS
Listed
2009-10-08

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.